companydata.dkcompanydata.dk

Incyte Biosciences Denmark ApS: Financial statements 2025

CVR: 35818790

Source: annual report 2025, Danish Business Authority

01/01/2025 – 31/12/2025

Incyte Biosciences Denmark ApS (CVR 35818790) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 6,696,586 and a net result of DKK 361,151 compared with DKK 368,873 the year before. That is a decrease of 5% compared with the year before. Equity in the 2025 report amounted to DKK 2,328,496. The solvency ratio was 58.1%. The company had 4 employees in the financial year.

Gross Profit
DKK 6,696,586
Profit/Loss
DKK 361,151
Equity
DKK 2,328,496
Total Assets
DKK 4,009,953
Employees
4

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2025-6.7M361K2.3M4
2024-7M369K2M4
2023-6.3M375K1.6M4
2022-5.6M278K1.2M4
2021-5.3M269K946K4

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is Incyte Biosciences Denmark ApS?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2025

Incyte Biosciences Denmark ApS: The 2024 annual report is outJun 26, 2025

Incyte Biosciences Denmark ApS has published its annual report for 2024. Gross profit came to DKK 7,046,348, and the net result was DKK 368,873.

Erik Garardus Johannes Bokmans joins the board of Incyte Biosciences Denmark ApSFeb 27, 2025

As of February 27, 2025, Erik Garardus Johannes Bokmans has joined the board of directors of Incyte Biosciences Denmark ApS.

Erik Thomas Fromm leaves the board of Incyte Biosciences Denmark ApSFeb 27, 2025

As of February 27, 2025, Erik Thomas Fromm has left the board of directors of Incyte Biosciences Denmark ApS.

Erik Garardus Johannes Bokmans joins Incyte Biosciences Denmark ApS as directorFeb 27, 2025

As of February 27, 2025, Erik Garardus Johannes Bokmans is registered as director of Incyte Biosciences Denmark ApS.

Erik Thomas Fromm steps down as director of Incyte Biosciences Denmark ApSFeb 27, 2025

As of February 27, 2025, Erik Thomas Fromm has stepped down as director of Incyte Biosciences Denmark ApS.

About Incyte Biosciences Denmark ApS

Incyte Biosciences Denmark ApS is a Danish company of the type Anpartsselskab based in Frederiksberg C, founded in 2014. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named ARIAD PHARMACEUTICALS (DENMARK) ApS. The management consists of Ebba Cecilia Bröms. The board consists of Lee Jason Heeson (chair) and Ebba Cecilia Bröms. The company is owned by Incyte Biosciences International Sàrl. The company has 4 employees (2026). In 2025, the company reported a gross profit of DKK 6,696,586 and a net result of DKK 361,151 compared with DKK 368,873 the year before. Equity in the 2025 report amounted to DKK 2,328,496.

Source: annual report 2025, Danish Business Authority